Advertisement

Depletion of collagen by losartan to improve tumor accumulation and therapeutic efficacy of photodynamic nanoplatforms

  • Yuxia Tang
  • Ying Liu
  • Shouju WangEmail author
  • Ying Tian
  • Yanjun Li
  • Zhaogang TengEmail author
  • Guangming LuEmail author
Original Article
  • 19 Downloads

Abstract

Nanocarriers for drug delivery have made great progress in the treatment of cancer, but the dense extracellular collagen of tumors has greatly limited the efficiency of drug delivery. In this study, losartan is used to deplete tumor collagen and improve the delivery efficiency and photodynamic therapeutic efficacy of chlorine 6 (Ce6)-loaded periodic mesoporous organosilica nanoplatform (Ce6-PMO) for breast cancer. After pretreatment with losartan in vivo, the tumor collagen I fraction is significantly reduced by 53% compared to that of mice pretreated with saline. Importantly, the accumulation of the Ce6-PMO nanoplatforms in the tumor is remarkably enhanced via peritumoral and intravenous injection, respectively, after the mice are pretreated with losartan. Further, combination of losartan with the Ce6-PMO nanoplatforms shows the best therapeutic efficacy, and the suppression rate of tumor volume is measured up to 82%. Taken together, this study provides a very promising synergetic strategy to improve the tumor photodynamic treatment efficacy of nanoplatforms.

Keywords

Losartan Photodynamic therapy Periodic mesoporous organosilica Breast cancer 

Notes

Acknowledgements

This study received financial support from the National Key Basic Research Program of the PRC (2014CB744501 and 2014CB744504), the National Natural Science Foundation of China (81601555, 81601554, 81501537, and 8140070836).

Compliance with ethical standards

All institutional and national guidelines for the care and use of laboratory animals were followed.

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

13346_2018_610_MOESM1_ESM.docx (200 kb)
ESM 1 (DOCX 199 kb)

References

  1. 1.
    Allison RR. Photodynamic therapy: oncologic horizons. Future Oncol. 2014;10:123–4.CrossRefGoogle Scholar
  2. 2.
    Zhang X, Liu T, Li Z, Zhang X. Progress of photodynamic therapy applications in the treatment of musculoskeletal sarcoma (review). Oncol Lett. 2014;8:1403–8.CrossRefGoogle Scholar
  3. 3.
    Chilakamarthi U, Giribabu L. Photodynamic therapy: past, present and future. Chem Rec. 2017;17:775–802.CrossRefGoogle Scholar
  4. 4.
    Fa W, Huang P, Chen X. Overcoming the Achilles’ heel of photodynamic therapy. Chem Soc Rev. 2016;45:6488–519.CrossRefGoogle Scholar
  5. 5.
    Benov L. Photodynamic therapy: current status and future directions. Med Princ Pract. 2015;24:14–28.CrossRefGoogle Scholar
  6. 6.
    Sagnella SM, McCarroll JA, Kavallaris M. Drug delivery: beyond active tumour targeting. Nanomedicine:NBM. 2014;10:1131–7.CrossRefGoogle Scholar
  7. 7.
    Chauhan VP, Stylianopoulos T, BoucherY, Jain RK. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng 2011; 2: 281–298.Google Scholar
  8. 8.
    Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol. 2013;31:2205–18.CrossRefGoogle Scholar
  9. 9.
    Stylianopoulos T, Martin JD, Chauhan VP, Jain SR, Diop-Frimpong B, Bardeesy N, et al. Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci. 2012;109:15101–8.CrossRefGoogle Scholar
  10. 10.
    Mckee TD, Grandi P, Mok W, et al. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res. 2006;66(5):2509–13.CrossRefGoogle Scholar
  11. 11.
    Ganesh S, Edick MG, Idamakanti N, Abramova M, VanRoey M, Robinson M, et al. Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer Res. 2007;67:4399–407.CrossRefGoogle Scholar
  12. 12.
    Mok W, Boucher Y, Jain RK. Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus. Cancer Res. 2007;67:10664–8.CrossRefGoogle Scholar
  13. 13.
    Diop-Frimpong B, Chauhan VP, Krane S, Boucher Y, Jain RK. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc Natl Acad Sci. 2011;108:2909–14.CrossRefGoogle Scholar
  14. 14.
    Cun X, Ruan S, Chen J, Zhang L, Li J, He Q, et al. A dual strategy to improve the penetration and treatment of breast cancer by combining shrinking nanoparticles with collagen depletion by losartan. Acta Biomater. 2016;31:186–96.CrossRefGoogle Scholar
  15. 15.
    Xiao L, Hu SQ, Wang LY, Liu JX, Li XY. Losartan improves the distribution and efficacy of doxorubicin in CT26 tumor. Eur Rev Med Pharmacol Sci. 2015;19:3763–9.Google Scholar
  16. 16.
    Zhang L, Wang Y, Yang Y, Liu Y, Ruan S, Zhang Q, et al. High tumor penetration of paclitaxel loaded pH sensitive cleavable liposomes by depletion of tumor collagen i in breast cancer. ACS Appl Mater Interfaces. 2015;7:9691–701.CrossRefGoogle Scholar
  17. 17.
    Huang P, Chen Y, Lin H, Yu L, Zhang L, Wang L, et al. Molecularly organic/inorganic hybrid hollow mesoporous organosilica nanocapsules with tumor-specific biodegradability and enhanced chemotherapeutic functionality. Biomaterials. 2017;125:23–37.CrossRefGoogle Scholar
  18. 18.
    Du X, Li X, Xiong L, Zhang X, Kleitz F, Qiao SZ. Mesoporous silica nanoparticles with organo-bridged silsesquioxane framework as innovative platforms for bioimaging and therapeutic agent delivery. Biomaterials. 2016;91:90–127.CrossRefGoogle Scholar
  19. 19.
    Teng Z, Zhang J, Li W, Zheng Y, Su X, Tang Y, et al. Facile synthesis of yolk-Shell-structured triple-hybridized periodic mesoporous Organosilica nanoparticles for biomedicine. Small. 2016;12:3550–8.CrossRefGoogle Scholar
  20. 20.
    Tang Y, Teng Z, Liu Y, Tian Y, Sun J, Wang S, et al. Cytochrome C capped mesoporous silica nanocarriers for pH-sensitive and sustained drug release. J Mater Chem B. 2014;2:4356–62.CrossRefGoogle Scholar
  21. 21.
    Zhang L, Wang Y, Xia T, Yu Q, Zhang Q, Yang Y, et al. Suppression for lung metastasis by depletion of collagen I and lysyl oxidase via losartan assisted with paclitaxel-loaded pH-sensitive liposomes in breast cancer. Drug Deliv. 2016;23(8):2970–9.CrossRefGoogle Scholar
  22. 22.
    Grossman M, Ben-Chetrit N, Zhuravlev A, Afik R, Bassat E, Solomonov I, et al. Tumor cell invasion can be blocked by modulators of collagen fibril alignment that control assembly of the extracellular matrix. Cancer Res. 2016;76(14):4249–58.CrossRefGoogle Scholar
  23. 23.
    Chauhan VP, Martin JD, Liu H, Lacorre DA, Jain SR, Kozin SV, et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun. 2013;4:2516–27.CrossRefGoogle Scholar
  24. 24.
    Michel MC, Foster C, Brunner HR, Liu L. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev. 2013;65:809–48.CrossRefGoogle Scholar

Copyright information

© Controlled Release Society 2019

Authors and Affiliations

  1. 1.Department of Medical Imaging, Jinling Hospital, Clinical School of Medical CollegeNanjing UniversityNanjingPeople’s Republic of China
  2. 2.State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical EngineeringNanjing UniversityNanjingPeople’s Republic of China

Personalised recommendations